Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
about
Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Adipose-derived mesenchymal st ...... safety and feasibility study.
@en
Adipose-derived mesenchymal st ...... safety and feasibility study.
@nl
type
label
Adipose-derived mesenchymal st ...... safety and feasibility study.
@en
Adipose-derived mesenchymal st ...... safety and feasibility study.
@nl
prefLabel
Adipose-derived mesenchymal st ...... safety and feasibility study.
@en
Adipose-derived mesenchymal st ...... safety and feasibility study.
@nl
P2093
P2860
P50
P921
P1433
P1476
Adipose-derived mesenchymal st ...... safety and feasibility study.
@en
P2093
Abdelkrim Hmadcha
Ana Cardesa
Antonio De la Cuesta
Antonio León
Bernat Soria
Carlos Arnaiz
Carlos Caparrós-Escudero
Cristina Medina
David Pozo
Francisco Javier Barón
P2860
P304
P356
10.1371/JOURNAL.PONE.0195891
P407
P577
2018-05-16T00:00:00Z